Expression of a splice variant of the receptor for GHRH in 3T3 fibroblasts activates cell proliferation responses to GHRH analogs
Open Access
- 2 January 2002
- journal article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 99 (1) , 196-200
- https://doi.org/10.1073/pnas.012590999
Abstract
The stimulatory effects of growth hormone-releasing hormone (GHRH) and the antiproliferative action of GHRH antagonists have been demonstrated in various cancers, but the receptors that mediate these responses are not clearly identified. Recently, we reported that human cancer cell lines express splice variants (SVs) of the receptors for GHRH. SV1 exhibits the greatest similarity to the pituitary GHRH receptor and is most likely to be functional. To ascertain whether SV1 mediates mitogenic effects on nonpituitary tissues, we expressed SV1 in 3T3 mouse fibroblasts and studied the properties of the transfected cells. Radioligand binding assays with 125I-labeled GHRH antagonist JV-1–42 detected high affinity (Kd = 0.58 ± 0.17 nM) binding sites for GHRH with a maximal binding capacity (Bmax) of 103 ± 17.4 fmol/mg of membrane protein in 3T3 cells transfected with pcDNA3-SV1, whereas the control cells transfected with the empty vector did not show any GHRH binding. Cell proliferation studies showed that cells expressing SV1 are much more sensitive to GHRH analogs than the pcDNA3 controls. Thus, the expression of SV1 augments the stimulatory responses to GHRH(1–29)NH2 or GHRH agonist JI-38 and inhibitory responses to GHRH antagonist JV-1–38 as compared with pcDNA3 controls. The stimulation of SV1-expressing cells by GHRH or JI-38 is followed by an increase in cAMP production, but no GH release occurs. Vasoactive intestinal peptide had no effect, and its antagonist JV-1–53 did not inhibit the proliferation of SV1-expressing cells stimulated by GHRH. Our results suggest that SV1 could mediate responses of nonpituitary cells and various tumors to GHRH and GHRH antagonists. The presence of SV1 in several human cancer cell lines provides a rationale for antitumor therapy based on the blockade of this receptor by specific GHRH antagonists.Keywords
This publication has 34 references indexed in Scilit:
- Antagonists of GHRH Decrease Production of GH and IGF-I in MXT Mouse Mammary Cancers and Inhibit Tumor GrowthEndocrinology, 2001
- Antagonists of Growth Hormone-Releasing Hormone and Somatostatin Analog RC-160 Inhibit the Growth of the OV-1063 Human Epithelial Ovarian Cancer Cell Line Xenografted into Nude MiceJournal of Clinical Endocrinology & Metabolism, 2001
- Antagonists of growth hormone-releasing hormone arrest the growth of MDA-MB-468 estrogen-independent human breast cancers in nude miceBreast Cancer Research and Treatment, 2000
- Antagonists of growth hormone-releasing hormone (GH-RH) inhibit in vivo proliferation of experimental pancreatic cancers and decrease IGF-II levels in tumoursEuropean Journal Of Cancer, 2000
- Expression of Growth Hormone-Releasing Hormone (GHRH) Messenger Ribonucleic Acid and the Presence of Biologically Active GHRH in Human Breast, Endometrial, and Ovarian CancersJournal of Clinical Endocrinology & Metabolism, 1999
- Identification of Binding Domains of the Growth Hormone-Releasing Hormone Receptor by Analysis of Mutant and Chimeric Receptor ProteinsMolecular Endocrinology, 1998
- Inhibition of Growth of Human Osteosarcomas by Antagonists of Growth Hormone-Releasing HormoneJNCI Journal of the National Cancer Institute, 1995
- Standardized kinetic microassay to quantify differential chemosensitivity on the basis of proliferative activityZeitschrift für Krebsforschung und Klinische Onkologie, 1992
- Plasma growth hormone (GH)-releasing hormone levels in patients with lung carcinomaClinical Endocrinology, 1991
- Expression of human growth hormone-releasing factor in transgenic mice results in increased somatic growthNature, 1985